Fixed Phage Limited, a Glasgow, UK-based start up that develops products for treatment and prevention of infection and bacterial contamination in medicine, food safety, environmental sanitation and many other areas, is receiving a venture capital investment of undisclosed amount.
Investors include from Barwell PLC and Scottish Enterprise’s Scottish Co-Investment Fund.
Led by Dr CEO Jim Chadwick, Fixed Phage will commercialize a technology developed at the University of Strathclyde in Glasgow for tackling bacterial infection and contamination, including superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA).
At the beginning, the company will focus on wound care applications and wound dressings able to combat those bacteria.
The initial development of the technology was funded through the former Synergy Fund, owned by Strathclyde and the University of Glasgow, and through Scottish Enterprise’s Proof of Concept Programme.
Dr Mike Mattey, Honorary Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences is serving as CSO of Fixed Phage.